Power Law company profile

Gracell Biotechnologies

Biotech & Life Sciences · Huangpu, China · Founded 2017 · IPO 2021 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$704M

Market cap · 2026

Investors

15 investors on Gracell Biotechnologies's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage

6 Dimensions Capital

Series B+ 14 investors entered at this stage

Vivo Capital

Janus Henderson Investors

Adage Capital

Morningside

Logos Capital

Pivotal Life Sciences

TCGX

Lilly Asia Ventures

Wellington Management

RA Capital Management

OrbiMed

Exome Asset Management

King Star Capital

Temasek

Global footprint

Where Gracell Biotechnologies has talent and traffic

Web traffic by country

2.5K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Patent intelligence

$12M patent portfolio · 40 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$12M

1.7% of market cap · 2.2× smaller than top peer Kymera Therapeutics ($26M)

40 active patent families

Where Gracell Biotechnologies innovates BiochemistryMolecular biologyAntigen receptorImmune effectorTherapeutic effect

Above peer median on Legal, Strategic, Economic, Technology

Quality vs same-sector peers

Gracell Biotechnologies on the five Patsnap quality dimensions

Gracell Biotechnologies in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Gracell Biotechnologies concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Gracell Biotechnologies and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Gracell Biotechnologies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo